The second report (see page 501) assessed medical records of 734 patients with inflammatory bowel disease (IBD), the majority with Crohn’s disease, treated with infliximab during 14 years, and compared them with 666 patients who did not receive infliximab followed during this period.2 Median follow-up was more than twice as long for controls than for infliximab patients (58 months; 33–88 months). A total of 113 severe adverse events occurred in 93 treated patients, and 157 in 126 control patients. Mortality, malignancies and infection rates did not differ between the two populations. However, the control group was older and received steroids much more often during the much longer follow-up.